Genomic profiling of breast cancer in African-American women.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 11054-11054
Author(s):  
Raquel Nunes ◽  
Lynette Wray ◽  
Mihriye Mete ◽  
Thomas Godwin ◽  
Pia Maarit Herbolsheimer ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
African American ◽  
High Risk ◽  
African American Women ◽  
Triple Negative ◽  
Stage I ◽  
Mrna Levels ◽  
American Women ◽  
Basal Type

11054 Background: Molecular profiling of breast cancer (BC) identifies intrinsic subtypes with distinct gene expression and clinical characteristics. In the US, BC is less frequent in African-American females (AAF); however mortality is higher, particularly among younger women. Unfavorable subtypes of BC seem to be more frequent in premenopausal AAF. Methods: Tumor gene expression in AAF presenting with early stage or locally advanced BC was performed using the Symphony platform on fresh and paraffin-embedded tissue (Agendia inc), a microarray-based method which classifies tumors according to prognosis (MammaPrint, MP), molecular subtype (BluePrint, BP) and estrogen receptor (ER), progesterone receptor (PR) and Human Epidermal Growth Factor Receptor 2 (HER2) mRNA levels (TargetPrint, TP). Genomic information is correlated with clinical and pathologic characteristics and Oncotype DX recurrence score (RS) when available. We plan to enroll 100 patients. Results: Results available in 46 patients. Median age 62 years (range 24-100), 20 stage I, 15 stage II, 11 stage III disease. There was no significant association between MP risk and stage, but MP risk was significantly associated with grade 3 disease (p=.006). 9 cancers were triple negative by IHC; using BP, 8 of these were Basal-type and 1 HER2-type. Basal-type was the most common subtype in patients ≤ 40 years old (p < .001). In the 6 cases ER positive by IHC but negative by TP, 3 were Basal-type and 3 were HER2-type.14 patients had Oncotype RS results available: 2 were High Risk by Oncotype and MP; 3 had intermediate RS, 2 of which were High Risk by MP; 9 had a low RS, 4 of which were High Risk by MP. Conclusions: African-American women with stage I to III BC often present with High-Risk disease irrespective of stage. BP classified all young patients (≤40) as Basal-type. Molecular subtyping confirmed the biologic heterogeneity in triple negative and hormone positive tumors. Oncotype RS and MP offered different prognostic information. Follow up will be needed to determine correlation with outcome. Funding: MP, BP and TP test provided by Agendia. Biostatistical support by GHUTTCS-CTSA. [Table: see text]

Abstract 1465: Regulatory role of miRNA-661 in triple-negative breast cancer of African American women

2017 ◽  
Author(s):  
Aline S. Fonseca ◽  
Selene Elifio-Esposito ◽  
Marilesia F. Souza ◽  
Akanksha Mahajan ◽  
Yara R. Zabala ◽  
...  
Keyword(s):  
Breast Cancer ◽  
African American ◽  
African American Women ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Regulatory Role ◽  
American Women

scholarly journals LXR/RXR pathway signaling associated with triple-negative breast cancer in African American women

2018 ◽  
Vol Volume 11 ◽  
pp. 1-12 ◽  
Author(s):  
Odalys Torres-Luquis ◽  
Krystal Madden ◽  
N'sanh MR N'dri ◽  
Richard Berg ◽  
Olufunmilayo F. Olopade ◽  
...  
Keyword(s):  
Breast Cancer ◽  
African American ◽  
African American Women ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
American Women

Triple-negative early-stage breast cancer in African American women: A fuel to the fire

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 11039-11039 ◽  
Author(s):  
A. M. Khan ◽  
I. Sabnani ◽  
P. Tsang ◽  
D. A. Baran ◽  
E. Rogers-Phillips ◽  
...  
Keyword(s):  
Breast Cancer ◽  
African American ◽  
African American Women ◽  
Triple Negative ◽  
Early Stage ◽  
Early Stage Breast Cancer ◽  
American Women

Clinical outcome of triple-negative early breast cancer in a non-African American women cohort: More fuel to the fire.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. e11066-e11066
Author(s):  
E. Gil Deza ◽  
F. Tognelli ◽  
M. Abal ◽  
H. Japaze ◽  
E. L. Morgenfeld ◽  
...  
Keyword(s):  
Breast Cancer ◽  
African American ◽  
Clinical Outcome ◽  
African American Women ◽  
Early Breast Cancer ◽  
Triple Negative ◽  
American Women

BRCA1/2 in High-Risk African American Women with Breast Cancer: Providing Genetic Testing through Various Recruitment Strategies

2008 ◽  
Vol 12 (3) ◽  
pp. 401-407 ◽  
Author(s):  
Tuya Pal ◽  
Susan Vadaparampil ◽  
Judy Betts ◽  
Cheryl Miree ◽  
Song Li ◽  
...  
Keyword(s):  
Breast Cancer ◽  
African American ◽  
Genetic Testing ◽  
High Risk ◽  
African American Women ◽  
Recruitment Strategies ◽  
American Women

scholarly journals Factors Influencing Breast Cancer Genetic Testing Among High Risk African American Women: A Systematic Review

2019 ◽  
Author(s):  
Shirley Spencer ◽  
Carolyn Rodgers ◽  
Vickii Coffey
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
African American ◽  
Genetic Testing ◽  
High Risk ◽  
African American Women ◽  
Integrative Model ◽  
Cancer Genetic ◽  
American Women

African American women are disproportionately impacted by breast cancer and its associated effects. They have the highest breast cancer mortality rate of all racial and ethnic groups in the U.S., yet, many high risk African American women do not follow-up with genetic testing despite, having a shorter survival rate and more likely to develop malignancies or aggressive forms of breast cancer than white women. Purpose: This review explored breast cancer genetic follow up and barriers among African American women and made recommendations for designing tailored high risk breast cancer programs. Method: The Integrative Model of Behavioral Prediction framework provided the framework for the review. PubMed, PSYINFO, CINAHL and Cochrane Collection Plus databases were searched for articles published from 2007 to 2017 that focused on attitude and beliefs that influenced genetic testing follow up among African American women. Three reviewers independently reviewed and appraised articles. The quality of the articles was assessed to determine the evidence level and overall recommendations using the Joanna Bridge Institute grading criteria. Results: Sixteen of the 2275 articles reviewed met the inclusion criteria of which, seven showed statistically significance changes related to family concerns, medical mistrust and cost barriers; decreases in breast cancer worry and perceived risk after genetic counseling; and higher education level and diagnosed early increased genetic testing. Conclusions: This systematic review provides greater understanding of how the social determinants of health influence decisions about genetic testing and treatment to determine why African American women who are at risk for breast cancer, do not progress to genetic testing. It provided recommendations for designing sensitive curriculum content for African American women and providers to increase genetic follow-up and reduce breast cancer disparity. The results of this review could be used to design comprehensive, tailored interventions to address the identified barriers, increase breast cancer awareness and early detection, and help minority women make informed, value decisions about genetic testing and treatment options. Recommendations: Future research is required to examine the role communities, agencies and policy makers play in improving clinical outcomes for minorities.

scholarly journals CmP signaling network unveils novel biomarkers for triple negative breast cancer in African American women

2021 ◽  
Author(s):  
Johnathan Abou-Fadel ◽  
Brian Grajeda ◽  
Xiaoting Jiang ◽  
Alyssa-Marie Cailing-De La O ◽  
Esmeralda Flores ◽  
...  
Keyword(s):  
Breast Cancer ◽  
African American ◽  
African American Women ◽  
Triple Negative Breast Cancer ◽  
Breast Cancer Cells ◽  
Triple Negative ◽  
Breast Cancer Mortality ◽  
Signaling Network ◽  
American Women ◽  
Novel Biomarkers

Breast cancer is the most commonly diagnosed cancer worldwide and remains the second leading cause of cancer death. While breast cancer mortality has steadily declined over the past decades through medical advances, an alarming disparity in breast cancer mortality has emerged between African American women (AAW) and Caucasian American women (CAW); and new evidence suggests more aggressive behavior of triple-negative breast cancer (TNBC) in AAW may contribute to racial differences in tumor biology and mortality. Progesterone (PRG) is capable of exerting its cellular effects through either its classic, non-classic or combined responses through binding to either classic nuclear PRG receptors (nPRs) or non-classic membrane PRG receptors (mPRs), warranting both pathways an equally important status in PRG-mediated signaling. In our previous report, we demonstrated that the CCM signaling complex (CSC) consisting of CCM1, CCM2, and CCM3 proteins can couple both nPRs and mPRs signaling cascades to form a CSC-mPRs-PRG-nPRs (CmPn) signaling network in nPR positive(+) breast cancer cells. In this report, we furthered our research by establishing the CSC-mPRs-PRG (CmP) signaling network in nPR(-) breast cancer cells, demonstrating that a common core mechanism exists, regardless of nPR(+/-) cell type. This is the first report stating that inducible expression patterns exist between CCMs and major mPRs in TNBC cells. Furthermore, we firstly show mPRs in TNBC cells are localized in the nucleus and participate in nucleocytoplasmic shuttling in a coordinately synchronized fashion with CCM proteins under steroid actions, following the same cellular distribution as other well-defined steroid hormone receptors. Finally, for the first time, we deconvoluted the CmP signalosome by using multi-omics approaches, which helped us understand key factors within the CmP network, and identify 21 specific biomarkers with potential clinical applications associated with AAW-TNBC tumorigenesis. These novel biomarkers could have immediate clinical implications to dramatically improve health disparities among AAW-TNBCs.

Triple negative breast cancer in African American women: Disparity between women in New Orleans versus Louisiana.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e12501-e12501 ◽  
Author(s):  
Michelle Marie Loch ◽  
John Estrada ◽  
Thomas Reske ◽  
Xiangrong Li ◽  
Vivien Chen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
African American ◽  
African American Women ◽  
New Orleans ◽  
White Women ◽  
Triple Negative ◽  
Her2 Status ◽  
Tumor Characteristics ◽  
Empirical Observation ◽  
American Women

e12501 Background: For years clinicians have made the empirical observation that there is an unusually high number of African American women (AAW) with triple-negative (Tneg) breast cancer (BC) in New Orleans (NO). Knowing the rate of Tneg BC in AAW is higher than white women (WW), we explored the hypothesis that AAW in NO have a higher rate of Tneg BC when compared to AAW in the rest of Louisiana (LA). Methods: We analyzed data from the Louisiana Tumor Registry, one of the NCI funded SEER registries, for the tumor characteristics of invasive female BC diagnosed in 2010, focusing on racial disparities; HER2 status was not available for prior to 2010 diagnosis. We explored the association of HER2 status with age, race, ER, PR, HER2, T, N, M to determine crude and adjusted odds ratios and rate distribution of subtypes using SEER*Stat and SAS programs. Results: Overall age-adjusted incidence rate of Tneg BC in AAW was 30 per 100,000 in NO, which was 24% higher than that in AAW in the rest of LA and two-fold the rate in WW of both NO and LA. The highest rate of Tneg BC was seen in AAW aged 65-69 in NO (184.97 per 100,000) compared with 81.5 per 100,000 in AAW aged 55-59 in LA. AAW with Tneg BC in NO were more likely to have more aggressive BC. Young age, black race, large tumor size, higher grade and TNM stage were significantly associated with the high risk of Tneg BC. After adjusting for age, geographic area, and other tumor characteristics, the higher risk of Tneg BC in AAW remained in NO compared with the rest of LA (OR=1.4; 95% CI: 1.01-1.87). Conclusions: AAW in NO are more likely to have poorly differentiated and Tneg BC compared to AAW in the rest of LA. This disparity remains when comparing our data to previously published literature in other parts of the US. We plan to continue our data analysis and compare NO data to the national average as the HER2 data become available in the SEER Program to better characterize the disparity. This newly identified disparity in the AAW population in NO has clinical implications and translational research potential as it enables us to broaden the understanding and treatment of this aggressive disease.

Sign in / Sign up

Export Citation Format

Share Document